Study guide

6.6 Respiratory Pharmacotherapy: Asthma, COPD, and Inhaled Therapy

PEBC Pharmacist Evaluating Examination Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Introduction & The Canadian Pharmacy Practice Landscape

1.1 PEBC EE Blueprint, Format, Scoring, and IPG Certification Pathway 1.2 The Canadian Healthcare System, Canada Health Act, and Drug Regulation 1.3 Canadian Pharmacy Regulatory Framework, NAPRA Standards, and Professional Legislation

2 Chapter 2: Pharmaceutics & Drug Delivery Systems

2.1 Physicochemical Principles, Solubility, Ionization, and Stability 2.2 Solid Dosage Forms, Formulation Science, and Modified-Release Technologies 2.3 Liquid and Semisolid Dosage Forms, Dispersions, and Topical Delivery 2.4 Sterile Product Principles, Parenteral Delivery, and Biopharmaceuticals 2.5 Pharmaceutical Quality: GMP, Stability Testing, and Bioequivalence

3 Chapter 3: Biopharmaceutics & Clinical Pharmacokinetics

3.1 Drug Absorption, Distribution, Metabolism, and Elimination (ADME) 3.2 Bioavailability, Bioequivalence, and Biopharmaceutics Classification System (BCS) 3.3 Pharmacokinetic Modeling, Parameters, and Dosing Calculations 3.4 Therapeutic Drug Monitoring (TDM) and Clinical Application

4 Chapter 4: Pharmacology, Toxicology & Pharmacogenetics

4.1 Autonomic and Central Nervous System Pharmacology 4.2 Cardiovascular, Renal, and Endocrine Pharmacology 4.3 Clinical Toxicology, Overdose Management, and Antidotes 4.4 Biologics, Biosimilars, and Pharmacogenetics

5 Chapter 5: Pathophysiology & Clinical Assessment

5.1 Clinical Laboratory Diagnostics, Biomarkers, and Vital Signs 5.2 Cardiovascular and Respiratory Pathophysiology 5.3 Endocrine, Renal, and Gastrointestinal Pathophysiology 5.4 Neurologic, Psychiatric, and Musculoskeletal Pathophysiology 5.5 Physical Assessment and Point-of-Care Testing

6 Chapter 6: Pharmacotherapy & Minor Ailments

6.1 Cardiovascular Pharmacotherapy & Evidence-Based Guidelines 6.2 Endocrine and Metabolic Pharmacotherapy 6.3 Infectious Diseases and Antimicrobial Stewardship 6.4 Neurologic, Psychiatric, and Pain Management Therapeutics 6.5 Minor Ailment Prescribing and Nonprescription Therapy 6.6 Respiratory Pharmacotherapy: Asthma, COPD, and Inhaled Therapy 6.7 Gastrointestinal and Hepatic Pharmacotherapy 6.8 Renal, Fluid, and Electrolyte Therapeutics 6.9 Musculoskeletal and Rheumatologic Pharmacotherapy 6.10 Dermatologic, Ophthalmic, and Ear-Nose-Throat Pharmacotherapy 6.11 Hematologic, Immunologic, and Oncology Supportive Care 6.12 Women's Health, Men's Health, and Urologic Therapeutics 6.13 Nutrition, Natural Health Products, and Complementary Medicine

7 Chapter 7: Special Populations & Applied Therapeutics

7.1 Geriatric Pharmacotherapy and Deprescribing 7.2 Pediatric and Neonatal Pharmacotherapy 7.3 Perinatal Pharmacotherapy: Pregnancy and Lactation 7.4 Dosage Adjustments in Renal and Hepatic Impairment

8 Chapter 8: Prescription Processing, Calculations & Compounding

8.1 Prescription Processing, Verification, and Drug Therapy Problem Management 8.2 Pharmaceutical Calculations and Clinical Math 8.3 Non-Sterile Compounding and NAPRA Standards 8.4 Sterile and Hazardous Compounding under NAPRA Standards 8.5 Advanced Calculations: Infusion Rates, Parenteral Nutrition, and Renal Estimation

9 Chapter 9: Health Equity, Indigenous Health & Pharmacy Bioethics

9.1 Social Determinants of Health and Health Equity 9.2 Indigenous Health, Cultural Safety, and Humility 9.3 Pharmacy Bioethics, Informed Consent, and Professional Boundaries 9.4 Health Promotion, Disease Prevention, and Public Health

10 Chapter 10: Evidence Appraisal, Safety & Practice Management

10.1 Biostatistics and Critical Appraisal of Clinical Literature 10.2 Pharmacoeconomics and Pharmacoepidemiology 10.3 Medication Safety, Incident Analysis, and Quality Improvement 10.4 Pharmacy Operations, Cold-Chain Management, and Emergency Preparedness 10.5 Drug Information and Evidence-Based Decision Making 10.6 Pharmacovigilance and Adverse Drug Reaction Reporting in Canada

11 Chapter 11: Patient Care Process, Communication & Collaborative Practice

11.1 The Patient Care Process: Assessment, Care Plans, and Follow-Up 11.2 Patient and Caregiver Communication, Education, and Health Literacy 11.3 Motivational Interviewing and Shared Decision-Making 11.4 Intra- and Interprofessional Collaborative Care

12 Chapter 12: Medication Administration, Devices & Expanded Scope

12.1 Injection and Vaccine Administration Technique 12.2 Immunization Schedules, Vaccine Selection, and Travel Health 12.3 Home Medical Devices and Device Technique Coaching 12.4 Expanded Scope: Adapting, Renewing, Initiating, and Medication Reconciliation

13 Chapter 13: Pharmacy Management, Finance & Practice Leadership

13.1 Human Resources, Leadership, and Change Management 13.2 Financial Management, Drug Plans, and Marketing 13.3 Quality Improvement, Risk Management, and Workplace Safety

6.6 Respiratory Pharmacotherapy: Asthma, COPD, and Inhaled Therapy

Key Takeaways Explain This Topic AI

Canadian Thoracic Society guidance makes anti-inflammatory reliever therapy (budesonide-formoterol used as needed) the preferred reliever across asthma severities in patients 12 years and older, replacing short-acting beta-2 agonist monotherapy.

Dispensing a patient more than two salbutamol inhalers per year is a validated marker of poor asthma control and should trigger reassessment of adherence, inhaler technique, and controller therapy.

COPD is confirmed by post-bronchodilator spirometry showing an FEV1/FVC ratio below 0.70; asthma is characterised by variable, largely reversible obstruction, and the two diagnoses require different starting therapy.

Inhaled corticosteroids are added in COPD mainly to reduce exacerbations in patients with a history of exacerbations or blood eosinophilia, and they raise pneumonia risk, so they are not first-line for every patient.

Every respiratory encounter must include a device-technique check, because incorrect inhaler technique is the single most common reversible cause of apparent treatment failure.

Last updated: August 2026

6.6 Respiratory Pharmacotherapy: Asthma, COPD, and Inhaled Therapy

Exam Focus: Respiratory conditions appear on the Evaluating Examination inside the Pharmacotherapeutics subcategory of Pharmacy Practice. Expect items that ask you to distinguish asthma from COPD on objective data, choose the next therapeutic step, recognise the traps of reliever overuse, and identify device-technique failures.

Asthma: Assessment and Control

Asthma is a chronic inflammatory airway disorder producing variable expiratory airflow limitation. Diagnosis in adults requires objective confirmation of variable obstruction, most commonly a post-bronchodilator increase in forced expiratory volume in one second (FEV1) of at least 12% and 200 mL.

Control, not severity, drives day-to-day therapeutic decisions. The Canadian Thoracic Society control criteria a pharmacist can assess at the counter are:

  • Control parameter Acceptable control
  • Daytime symptoms Fewer than 4 days per week
  • Night-time symptoms Fewer than 1 night per week
  • Reliever use Fewer than 4 doses per week
  • Physical activity Normal
  • Exacerbations Mild and infrequent
  • Absence from work or school None
  • FEV1 or peak expiratory flow At least 90% of personal best

A patient failing any single criterion has uncontrolled asthma. Before escalating drug therapy, work through the four reversible causes in order: adherence , inhaler technique , trigger exposure (smoke, occupational agents, pets, non-steroidal anti-inflammatory drugs in aspirin-exacerbated respiratory disease), and comorbidity (rhinitis, reflux, obesity).

Reliever strategy: the anti-inflammatory reliever shift

The most heavily tested change in modern asthma care is the move away from short-acting beta-2 agonist (SABA) monotherapy. Because every symptom episode reflects underlying inflammation, current Canadian guidance positions as-needed budesonide-formoterol (an inhaled corticosteroid combined with a fast-onset long-acting beta-2 agonist) as the preferred reliever in patients 12 years and older, either alone in mild disease or as both maintenance and reliever therapy (MART) in moderate to severe disease.

The practical dispensing signal is quantitative: filling more than two salbutamol inhalers in a year predicts exacerbation risk and, at higher volumes, mortality. Treat it as a hard trigger for assessment, not a routine refill.

Controller escalation

Low-dose inhaled corticosteroid (ICS) daily, or as-needed ICS-formoterol in mild disease.

Low-dose ICS plus a long-acting beta-2 agonist (LABA), ideally as MART.

Medium-dose ICS-LABA.

Add a long-acting muscarinic antagonist (tiotropium) or a leukotriene receptor antagonist.

Refer for biologic therapy phenotyped by blood eosinophils and immunoglobulin E (omalizumab, mepolizumab, benralizumab, dupilumab).

A LABA is never dispensed as monotherapy in asthma. It relieves bronchoconstriction while leaving inflammation untreated, and this combination is associated with increased asthma-related death.

Montelukast carries a boxed warning for serious neuropsychiatric events including agitation, sleep disturbance, aggression, and suicidal ideation. Counsel on this explicitly and document the discussion.

Chronic Obstructive Pulmonary Disease

COPD requires post-bronchodilator spirometry with an FEV1/FVC ratio below 0.70 . Symptoms alone are not diagnostic; a pharmacist who recommends therapy for "smoker's cough" without spirometry is skipping the diagnostic step the examination expects.

  • Feature Asthma COPD
  • Typical onset Childhood or early adult Usually after age 40
  • Dominant risk factor Atopy, allergen exposure Tobacco smoke, biomass, occupational dust
  • Reversibility Largely reversible Persistent, incompletely reversible
  • Symptom pattern Variable, episodic, often nocturnal Progressive, exertional dyspnea
  • Sputum eosinophils Often raised Usually neutrophilic
  • Response to ICS alone Substantial Limited; reserved for exacerbation reduction
  • Pharmacotherapy escalation in COPD

Low symptom burden, low exacerbation risk: short-acting bronchodilator as needed.

Persistent breathlessness: a long-acting muscarinic antagonist (LAMA) or LABA, then dual LAMA-LABA.

Recurrent exacerbations: add an ICS, giving triple ICS-LAMA-LABA therapy. Benefit is greatest with a history of exacerbations or blood eosinophils of roughly 0.3 x 10^9/L or higher.

Further exacerbations despite triple therapy: consider roflumilast in chronic bronchitis with an FEV1 below 50%, or long-term azithromycin.

Inhaled corticosteroids increase pneumonia risk in COPD, so the decision to add or continue them is an explicit risk-benefit judgement and a legitimate deprescribing target in a patient who has never exacerbated.

Only three interventions alter COPD mortality: smoking cessation , long-term oxygen therapy in documented chronic hypoxemia , and lung volume reduction surgery in selected patients . Pharmacotherapy improves symptoms and reduces exacerbations. Smoking cessation is therefore a therapeutic intervention, not an aside, and pharmacists in every province can support it with varenicline, bupropion, and nicotine replacement combinations.

Managing an acute exacerbation

Increase short-acting bronchodilators, add prednisone 40 mg daily for 5 days, and add an antibiotic when sputum becomes purulent and increases in volume alongside worsening dyspnea. Extended corticosteroid courses provide no additional benefit and increase harm.

Cystic Fibrosis

Cystic fibrosis results from mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene, producing viscous secretions, obstructive lung disease, chronic Pseudomonas aeruginosa infection, and pancreatic insufficiency. Pharmacist-relevant therapy includes airway clearance with dornase alfa and hypertonic saline, inhaled tobramycin for chronic Pseudomonas , pancreatic enzyme replacement taken with every meal and snack, fat-soluble vitamin supplementation (A, D, E, K), and CFTR modulators such as elexacaftor-tezacaftor-ivacaftor, which are selected by genotype rather than by symptoms.

Device Selection and Technique

Device technique is a therapeutic variable, not a courtesy.

Device Critical technique point Common failure

Pressurised metered-dose inhaler Slow deep inhalation coordinated with actuation Poor coordination; fires into the mouth

MDI with valved holding chamber Actuate once, then 5 tidal breaths or one slow deep breath Multiple actuations into the chamber

Dry powder inhaler Forceful, deep inhalation; keep the device dry Exhaling into the mouthpiece, ruining the dose

Soft mist inhaler Slow steady inhalation; device must be primed Skipping the priming step

Counsel every patient on an ICS-containing product to rinse and spit after use to prevent oropharyngeal candidiasis and dysphonia. A spacer reduces both oropharyngeal deposition and systemic exposure.